Orally administered terazosin is indicated in adults as a therapy for the symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH).
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64) Elders (65+)
Oral, 1 milligrams, once daily at the end of the day. Afterwards, oral, between 5 and 10 milligrams, once daily at the end of the day. The maximum allowed total dose is 10 milligrams daily.
The dose of terazosin should be adjusted according to the patient’s response. The following is a guide to administration:
Initial dose: 1mg before bedtime is the starting dose for all patients and should not be exceeded. Strict compliance with this recommendation should be observed to minimise acute first-dose hypotensive episodes.
Subsequent dose: The dose may be increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms. The maintenance dose is usually 5 to 10mg once daily. Improvements in symptoms have been detected as early as two weeks after starting treatment with terazosin.
At present there are insufficient data to suggest additional symptomatic relief with doses above 10mg once daily.
Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.